Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: In addition to lifestyle recommendations, they will receive a daily dose of 50 mg of Sitagliptin manufactured by Tehran Daroo Company for one year. Intervention 2:
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: People over the age of 18 who are diagnosed with grade 2 or 3 fatty liver on primary ultrasound for patients. People with liver enzymes with ALT above 30 in women and above 40 in men.
Exclusion criteria
Exclusion criteria: Evidence of viral hepatitis (such as hepatitis B surface antigen positive and RNA positive for hepatitis C) Medicinal hepatitis and autoimmune hepatitis HbA1C hemoglobin level higher or equal to 5.6% History of diabetes Wilson's Disease A history of diabetes (fasting blood sugar high or equal to 126 mg / dL) Hemochromatosis Regular consumption of alcohol Evidence of untreated liver cirrhosis and severe liver disease APRI above or equal to 2 Patients who were already treated with sitagliptin or vitamin E
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biochemical tests (ALT, AST, ALKP, GGT, Bili total, Bili Direct, FBS, Insulin, Ferritin, HDL, LDL, TG, Chol). Timepoint: Before and after treatment. Method of measurement: Test.;Hematological tests. Timepoint: Before and after treatment. Method of measurement: Test.;Demographic characteristics. Timepoint: Before and after treatment. Method of measurement: Questionnaire.;Fatty liver grade. Timepoint: Before and after treatment. Method of measurement: Device Fibrous Scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Nejadisalami
Iran University of Medical Sciences
Outcome results
None listed